Sunday, October 24, 2021


BioNTech to seek approval soon for vaccine for 5-11 year olds

BioNTech, which collaborates with Pfizer, holds the lead in the race to win broad approval to vaccinate children below the age of 12 in Western countries.

No need yet to adapt Pfizer vaccine for Covid variants, says BioNTech chief

He says a decision should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.

After Covid jab, BioNTech sets sights on malaria vaccine

If successful, the vaccine could be a crucial step in the fight against the mosquito-borne disease, which kills more than 400,000 people a year.

Taiwan’s chips too vital for war, says island’s major chipmaker

Taiwan's TSMC, the world's largest contract chipmaker is at the centre of global efforts to resolve chip shortages.

Pfizer-BioNTech to seek green light for third Covid shot

The companies are also developing a Delta-specific vaccine, with clinical studies expected to begin in August.

Taiwan says China’s anger at its use of ‘country’ caused BioNTech vaccine deal collapse

China considers Taiwan its own territory and strongly objects to any reference that implies Taiwan is a separate country.

Covid jab maker BioNTech to build factory in Singapore

Construction of the manufacturing plant will start this year and the site could be operational by 2023.

Pfizer draws criticism as profits from Covid-19 jab sales soar

Pfizer is holding talks with 'basically all governments of the world' about providing booster shots through 2024.

Pfizer-BioNTech seek Covid jab approval for teens aged 12-15 in EU

While children and teenagers are less likely to develop severe Covid, they make up a large part of the population and inoculating them is considered key to ending the pandemic.

South African variant better at bypassing Pfizer-BioNTech jab, Israeli study shows

The South African variant is able, to some extent, to break through the vaccine's protection, they say.

Pfizer seeks Covid vaccine green light for 12 to 15-year-olds in US

Phase 3 clinical trials of the Pfizer vaccine in 12 to 15-year-olds show it is '100% effective' in warding off the disease.

BioNTech-Pfizer say Covid vaccine 100% effective on 12 to 15-year-olds

A younger cohort of two-to-five year olds are expected to get their first dose next week in the study which will also cover children as young as six months old.

Other News